Google
Trusted Resources: News & Events
Latest announcements and gatherings
Emmaus Life Sciences Launches Its Commercial Co-Payment Assistance Program for Endari™
Emmaus Life Sciences, Inc., a leader in sickle cell disease treatment, announced today that it will provide financial assistance to help eligible patients afford their monthly co-payment for Endari™ (L-glutamine oral powder)1. The program is limited to financially eligible patients covered by commercial insurance.
A significant number of individuals with sickle cell disease are covered by commercial insurance. In some cases, patients may have difficulty affording the monthly co-payment amount.
Mark Diamond, Emmaus’ Vice President of Commercialization, commented: “We are committed to removing barriers between patients and Endari – giving a greater number of patients access to our effective treatment for sickle cell disease.”
+myBinderRelated Content
-
Improving the Quality of Care for Adolescents and Adults With Sickle Cell Disease—It’s a Long RoadThe World Health Organization defines qu...
-
Representative Johnson Files Four Sickle Cell Disease Related BillsState Representative Jarvis Johnson (HD ...
-
Gary A. GibsonGary A. Gibson has accumulated forty yea...
-
Sick CellsSick Cells' mission is to elevate the vo...
-
Current Advocacy Work in Sickle Cell Disease: The Global PerspectiveJoin the Global Alliance of Sickle Cell ...
-
Sickle Cell and Thalassaemia Support Group of Barking, Dagenham and HaveringWe are the Sickle Cell and Thalassaemia ...
-
Proclamation on National Sickle Cell Disease Awareness Month, 2020 – By the President of the United States of ...As our nation recognizes National Sickle...
To improve your experience on this site, we use cookies. This includes cookies essential for the basic functioning of our website, cookies for analytics purposes, and cookies enabling us to personalize site content. By clicking on 'Accept' or any content on this site, you agree that cookies can be placed. You may adjust your browser's cookie settings to suit your preferences. More Information
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.
Powered by
Support for this site is provided by
This platform is made possible through a partnership with the Sickle Cell Disease Association of America, Inc. (SCDAA) and its member organizations. SCDAA's mission is to advocate for people affected by sickle cell conditions and empower community-based organizations to maximize quality of life and raise public consciousness while advancing the search for a universal cure.